NCT02000427 2024-05-28Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic LeukemiaAmgenPhase 2 Completed45 enrolled 24 charts 1 FDA
NCT02013167 2024-03-05Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Terminated405 enrolled 27 charts 1 FDA